Last 20 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.05 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | 11.03 | — | — | — | 58.44 | — | — | — |
| — | — | — | — | — | -81.1% | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | 5.34 | 0.24 | 0.14 | 0.34 | 0.36 | 0.42 | 0.33 | 0.20 | 0.22 | 0.18 |
| — | — | — | +1367.4% | -42.4% | -59.0% | +66.0% | +66.8% | +129.9% | +131.2% | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 50.0% | — | — | — | 83.3% | — | — | — |
| — | — | — | — | — | -40.0% | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | -4933.7% | — | — | — | -11386.0% | — | — | — |
| — | — | — | — | — | +56.7% | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | -5451.7% | — | — | — | -85503.2% | — | — | — |
| — | — | — | — | — | +93.6% | — | — | — | — | — | — | — |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -31.1% | -27.1% | -18.3% | -30.7% | -27.9% | -25.4% | -86.7% | -14.6% | -134.0% | -3.6% |
| — | — | — | -11.6% | -6.9% | +78.9% | -110.3% | +79.2% | -605.0% | -698.1% | — | — | +70.8% | |
| ROA | -13542.7% | -0.4% | -191.5% | -10.9% | -10.9% | -7.1% | -12.3% | -13.4% | -12.9% | -48.5% | -9.0% | -106.9% | -3.0% |
| — | +94.5% | -1451.1% | +19.0% | +16.0% | +85.4% | -37.9% | +87.4% | -325.5% | -512.4% | +94.9% | -2.4% | +67.4% | |
| ROIC | — | — | — | -24438.7% | -23820.9% | -13.9% | -22.1% | -23.4% | -24.7% | -10.2% | -11.4% | -111.8% | -3.6% |
| — | — | — | -104554.3% | -96168.6% | -36.1% | -93.1% | +79.1% | -582.9% | -33.6% | — | — | +51.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 82.1% YoY to 0.03x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| — | — | — | — | — | — | — | — | — | -28.1% | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.03 | 0.03 | 0.08 | 0.04 | 0.18 | 0.15 | 0.03 | 0.06 | 0.30 | 0.33 | 0.17 | 0.11 | 0.33 |
| — | -82.1% | +130.5% | -32.6% | -41.9% | -53.6% | -80.3% | -39.7% | -8.4% | -57.7% | +112.0% | +4.5% | +307.1% | |
| Quick Ratio | 0.03 | 0.03 | 0.08 | 0.04 | 0.18 | 0.15 | 0.03 | 0.06 | 0.30 | 0.33 | 0.17 | 0.11 | 0.33 |
| — | -82.1% | +130.5% | -32.6% | -41.9% | -53.6% | -80.3% | -39.7% | -8.4% | -57.7% | +112.0% | +4.5% | +307.1% | |
| Interest Coverage | -49.28 | -3.23 | -156.27 | -16.01 | -18.88 | -9.32 | -17.24 | — | -27986.50 | — | -13822.28 | -16400.64 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 20 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying ZVSA stock.
ZyVersa Therapeutics, Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ZyVersa Therapeutics, Inc.'s business trajectory between earnings reports.